Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Among authors: sonke gs. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: sonke gs. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
Tannock IF, Bouche G, Goldstein DA, Goto Y, Lichter AS, Prabhash K, Ranganathan P, Saltz LB, Sonke GS, Strohbehn GW, von Moos R, Ratain MJ. Tannock IF, et al. Among authors: sonke gs. Ann Oncol. 2023 Aug;34(8):638-644. doi: 10.1016/j.annonc.2023.05.006. Epub 2023 May 23. Ann Oncol. 2023. PMID: 37230253 Free article. No abstract available.
Non-inferiority trials: tyranny or good governance? - Authors' reply.
Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, Saltz LB, Sonke GS, Strohbehn GW. Tannock IF, et al. Among authors: sonke gs. Lancet Oncol. 2025 Jan;26(1):e8. doi: 10.1016/S1470-2045(24)00717-4. Lancet Oncol. 2025. PMID: 39756458 No abstract available.
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, Guerrero Paez C, Mol L, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik-van de Mheen C, Tol J, Tromp-van Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Konings IR, Jager A; SONIA Study Consortium. Sonke GS, et al. Nature. 2024 Dec;636(8042):474-480. doi: 10.1038/s41586-024-08035-2. Epub 2024 Nov 27. Nature. 2024. PMID: 39604725 Clinical Trial.
The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy.
Van Maaren MC, Hueting TA, van Uden DJP, van Hezewijk M, de Munck L, Mureau MAM, Seegers PA, Voorham QJM, Schmidt MK, Sonke GS, Groothuis-Oudshoorn CGM, Siesling S; NABOR project group. Van Maaren MC, et al. Among authors: sonke gs. Breast. 2024 Oct 28;79:103829. doi: 10.1016/j.breast.2024.103829. Online ahead of print. Breast. 2024. PMID: 39541608 Free PMC article.
275 results